Home / Transcripts / ALK-Abelló A/S (ALKB) · May 4, 2026

ALK-Abelló A/S (ALKB) Earnings Call Transcript & Summary

May 4, 2026

Nasdaq Copenhagen DK Health Care Pharmaceuticals earnings 43 min

What were the key takeaways from ALK-Abelló A/S's May 4, 2026 earnings call?

ALK-Abelló A/S reported a strong Q1 2026, with revenue and earnings exceeding the upper end of their guidance. Revenue grew by 18% to DKK 1.8 billion, and EBIT increased by 22% to DKK 570 million, resulting in a 32% EBIT margin. The company achieved a milestone with tablet sales surpassing DKK 1 billion in a single quarter. Management upgraded the full-year revenue growth outlook to 13%-16% from 11%-15% and the EBIT margin to around 26%.

What topics did ALK-Abelló A/S cover?

What were ALK-Abelló A/S's May 4, 2026 results?

ALK-Abelló A/S delivered a robust Q1 2026, driven by strong tablet sales and strategic advancements in their allergy programs. The upgraded guidance reflects management's confidence in sustained growth, particularly in the tablet segment. Key risks include regulatory hurdles for neffy and potential pricing pressures in Germany. Investors should watch for developments in the peanut allergy program and further market access achievements for neffy as potential catalysts.

Earnings Call Speaker Segments

Per Plotnikof executive
#1

Hi, everyone, and thanks for being here for ALK's Q1 results presentation. We appreciate all of you joining. On slide 2, you'll find an introduction to the speakers and the agenda. I'm Per Plotnikof, Head of Investor Relations, and joining me are CEO Peter Halling and CFO Claus Steensen Sølje. Peter and Claus will take you through the highlights, markets, product trends, and financials, and following a strategic update focused on peanut allergy, our respiratory tablets, and the Neffy rollout, we'll move on to the full-year outlook. As always, we'll finish with a Q&A session. To begin, I'll pass it over to Peter on slide 3. Go ahead, Peter.

Peter Halling executive
#2

Thanks, Per, and thanks to everyone for joining this call. ALK got off to a very strong start this year, with revenue and earnings comfortably coming in above the top end of the full-year guidance range. EBIT was up 22%, giving a margin of 32%, supported by revenue growth of 18% to 1.8 billion Danish kroner. For the first time ever, ALK's total tablet sales topped 1 billion DKK in a single quarter. Results also got a lift from an improved gross margin, which reflects some seasonality in the sales mix, with a relatively high share of European tablet sales that carry higher margins. As guided, we expect this to normalize somewhat over the year as partner-related revenue increases. On the strategic side, the pediatric tablets are now marketed in most of our key European and North American geographies, and they are contributing increasingly to the inflow of new patients. Anaphylaxis sales also did well, especially with support from Jext. It is still early days for Neffy sales, but we continue to build market access, and we have secured further regulatory approvals, beginning with the 2 mg approval in Canada, an important market going forward, and the 1 mg version in the EU for younger children, also an important segment.

Peter Halling executive
#3

We anticipate that both will see their first launches during this year's second half. On April 20th, we unveiled the phase 2 results for our peanut allergy tablet that everyone had been waiting for. Finishing the trial successfully gives us a great deal of encouragement, and it marks an initial proof of concept for our tablet technology in food allergies. Given how strongly the year has begun, we have raised the full-year outlook. The presentation will go into all of this in more detail, but to start, I'll pass things to you, Claus, for the regional trends on slide 4.

Claus Steensen Sølje executive
#4

Thanks, Peter. Now let's dig a bit deeper into how the regions performed. Revenue in Europe rose 19%. Germany, which is the biggest AIT market in Europe, posted strong double-digit growth in tablets, and tablet sales in France likewise climbed by double digits, continuing the positive trend seen in recent years. That partly offsets a decline in SLIT-drops revenue in France. We also recorded high double-digit growth across several Eastern European countries and in the UK, where ACARIZAX and ITULAZAX gained admission to the NHS last year with general reimbursement. Within the EU, sales of anaphylaxis and other products rose 47%, and the anaphylaxis portfolio on its own was up 58%. The main driver was Jext, which benefited from higher replacement rates in the UK and earlier tender wins in Southern Europe. European Neffy revenue remained modest, since we are still building access across many markets, including the UK. We continue to expect uptake to increase as the year progresses. Revenue in North America grew 16% in local currencies, driven by double-digit growth in both the USA and Canada. This was fueled by strong demand for tablets in Canada across all brands and age groups. In the USA, revenue benefited from the cost compensation arrangement with ARS Pharma tied to the co-promotion of Neffy.

Claus Steensen Sølje executive
#5

When it comes to international markets, revenue was up 17% in local currencies. That growth came down to the timing of product shipments into China and Japan. SCIT shipments to China rose substantially versus Q1 2025, when they were paused while we renewed our import license. In Japan, we've gone through a stretch of soft growth tied to shipment phasing, capacity constraints, and the new owner standstill while the Torii takeover was being completed. In-market tablet sales that Shionogi records rose by double digits, and we're still comfortable that full-year tablet revenue growth from international markets will return to double digits, backed by Torii's expansion of API manufacturing capacity. Let's move on to slide 5 for the product lines. As Peter said, we hit a pretty impressive milestone in Q1. We're proud that tablet sales reached 1 billion DKK in a quarter for the very first time. In Europe, recent quarters have produced roughly 20% growth in tablet sales, but Q1 delivered 26% growth, driven mainly by higher volumes tied to a continued strong inflow of new patients over the past year. Sales across all tablet brands rose by double digits, and the biggest gross contribution came from ITULAZAX and ACARIZAX, increasingly fueled by the relatively new indications for children and adolescents.

Claus Steensen Sølje executive
#6

In North America, tablet sales were also up 26%, whereas international markets conversely experienced a 17% drop after reduced shipments of product to Japan, which was partly offset by double-digit revenue growth in the smaller tablet markets of Southeast Asia, the Middle East, and Australia. Sales of SCIT and SLIT-drops rose 15% to 566 million Danish kroner. Shipments of SCIT to China restarted after a pause last year, and European SCIT sales growth was primarily propelled by venom products. By contrast, SLIT-drop sales in France declined, as already mentioned. Anaphylaxis and other product sales climbed 31%, with very strong anaphylaxis-related revenue growth powered by the Jext autoinjector. Neffy contributed to that growth as well. Anaphylaxis-alone sales grew 84% globally. Let's now move to slide 6 for the financials. Revenue rose 18% in local currencies to almost 1.8 billion Danish kroner, on double-digit growth across every sales region and product line. Gross profit exceeding 1 billion Danish kroner produced a gross margin of 69%, up 2 percentage points, thanks to higher sales volumes, product mix changes, and production efficiencies. Higher-margin ALK-branded products made up a fairly high share of sales in Q1.

Claus Steensen Sølje executive
#7

But for the remainder of the year, we expect a larger portion of partner-related revenue carrying thinner margins. Capacity costs rose 23% in local currencies, reaching 658 million Danish kroner, following substantial spending on current and future growth initiatives — among them extra sales resources, as we noted on the Q4 earnings call. Operating profit came in 22% higher in local currencies at 570 million Danish kroner, lifting the EBIT margin to 32% from 31%. That improvement reflected greater sales and a better gross margin, while the ratio of capacity costs to revenue edged up slightly to 37%, consistent with what we forecast for 2026. Net profit grew to 437 million Danish kroner. Cash flow from operating activities totaled 761 million Danish kroner, driven primarily by stronger earnings and shifts in working capital. Free cash flow was positive, at 671 million Danish kroner. Overall, this was a very strong set of results, shaped by operational leverage and some seasonality, and it supports a high gross margin relative to the full-year guidance. Let's now move to slide 7 for the peanut allergy results and then to where our other strategic initiatives stand. Peter, please go ahead.

Peter Halling executive
#8

Thank you, Claus. The positive data from our phase 2 ALLIANCE study of the tablet in peanut allergy has us highly encouraged. This marks a significant milestone and, as I noted at the outset, represents the first proof of concept for ALK's tablet technology within food allergy. Clear dose-dependent, statistically significant efficacy was shown across multiple clinical endpoints, and never before has anyone demonstrated a convincing treatment effect with AIT in food allergy following only 6 months of treatment. We are, of course, also delighted that efficacy was seen across every age group, from children through to adults. Crucially, the treatment proved safe and well-tolerated, with low discontinuation rates and no treatment-related anaphylaxis or serious adverse events. On the strength of this data, we will move the peanut tablet rapidly into phase 3 clinical development, which we anticipate launching in the late part of '26, subject to regulatory feedback on the trial design. The FDA's fast track designation for this program should hopefully enable a constructive dialogue with the agency. Let me now briefly outline the unmet needs we are targeting. Peanut allergy is an immune defect in which even tiny quantities of peanut protein may set off dramatic and immediate reactions, including life-threatening anaphylaxis.

Peter Halling executive
#9

Usually, symptoms show up in early childhood and frequently persist as people get older. Among food allergies, this one ranks as especially serious and is a major trigger of anaphylaxis. At present, over 10 million individuals across Europe, the US, and Canada are living with peanut allergy, and children and adolescents account for more than 3 million of that group. Choices for treatment are still scarce. For a portion of these patients, tablets for sublingual immunotherapy could emerge as a meaningful alternative, with the possibility of enhancing quality of life for patients along with their families. Within our wider approach to the food allergy portfolio, we have likewise observed positive and encouraging headway on ALK-014. ALK-014 is a biologic candidate that targets the allergic immune response system. This project has the potential to enter clinical development in '27 and might be applied to food allergy along with other IgE-mediated allergic diseases. Put another way, an anti-IgE. Now, let's move on to slide 8 to examine more closely how other parts of our Allergy+ strategy are being executed. First, allow me to provide a quick update on our strategic initiatives in the respiratory area and anaphylaxis. Beginning with respiratory allergy, the pediatric tablet rollout keeps delivering strong results. By the end of Q1, the house dust mite tablet had launched in 21 markets, including North America, and the tree pollen tablet in 13 markets.

Peter Halling executive
#10

Our key performance indicators are still solid. In the markets we serve directly, over 4,000 prescribers have by now written at least one or two tablets for children. Roughly 20% of those physicians had never prescribed any ALK tablets before, and that tells us we're growing our prescriber base in existing markets. Now that tablets are launched in most key markets, the emphasis moves to deepening penetration and keeping prescriber adoption sustained. Our partnerships also keep moving forward. In China, patient recruitment for the ACARIZAX phase 3 trial has finished, and that trial should wrap up around the turn of the year. In Japan, the GRAZAX phase 3 trial is advancing toward completion in early '27. Let me take a moment on Neffy. Starting with regulatory progress: in Q1, the European Commission approved the 1 mg version of EURneffy for children aged 4 years and older who weigh between 15 and 30 kg. We anticipate the product's first launches in the second half of this year. That was a milestone, since EURneffy is Europe's first and only needle-free adrenaline treatment, and it is now offered in two dose strengths. Also, the 2 mg version won approval in Canada in April, with launches anticipated right after the summer.

Peter Halling executive
#11

Past the approvals stage, we're putting heavy effort into market access — really grinding through it, so to speak. In the UK, national approval and pricing got settled last year, though the UK is also a market where we have to ensure the product can be accessed and reimbursed at the local level. For patients to actually get it, the product must be listed across the UK's 42 local formularies. We're moving through that process in a systematic way, and it's expected to run through most of '26 and into '27. The UK is a big opportunity, but revenue contribution will build gradually starting in the second half of the year and continuing from there. One important UK highlight in Q1 was new legislation requiring all schools to keep adrenaline devices readily available for emergency cases. That legislation references both adrenaline autoinjectors and nasal sprays, including Neffy. In Germany, our first market, Neffy is bringing in revenue, and a solid market share has been held, even though we remain in the early market-shaping phase, working to shift longstanding prescribing habits. Turning to the US, the co-promotion agreement with ARS is moving forward, but it also confronts market access hurdles that must be overcome.

Peter Halling executive
#12

On a wider level, we're continuing work on market access and launch readiness across roughly 17 more countries. To wrap up on Neffy, Q1 revenue came in modest, which was anticipated, though we do expect a growing contribution from the second half of '26 and on into '27 as additional markets and regulations come online and open up new areas. With that, I'll pass it back to you, Claus, for the full-year outlook on slide 9.

Claus Steensen Sølje executive
#13

Thanks, Peter. We have raised our outlook for the full year on revenue, with greater confidence, driven by continued momentum in tablet sales, especially in Europe, while at the same time the risk picture has improved. Revenue is now projected to increase 13% to 16% in local currencies, compared with the prior outlook of 11% to 15% growth. The EBIT margin outlook has likewise been raised and is now anticipated at around 26%. We continue to devote substantial investment to initiatives aimed at strengthening growth and profitability over the long term. Among these are commercial investments in tablets, including the children rollout. In addition, we are investing in Neffy and building out the commercial infrastructure in the UK, Canada, and other markets. Beyond that, we are furthering our investments in AI. I would also emphasize that our long-term financial ambitions remain unchanged at present. Let me walk you through the key assumptions. We anticipate volume-driven revenue growth across sales regions and product groups. The bottom of the 13% to 16% range reflects macroeconomic uncertainty, including possible adverse effects from price and rebate adjustments, although this has been partly de-risked. It also incorporates slower growth in SCIT and SLIT-drops sales. The top of the range presumes stable price and rebate conditions plus potential upside for tablet and anaphylaxis sales.

Claus Steensen Sølje executive
#14

Like always, shipment schedules for overseas markets can cause quarter-to-quarter swings. We anticipate tablet sales will rise at a double-digit rate. Revenue from SCIT and SLIT-drops is forecast to increase at a single-digit rate, whereas anaphylaxis and other product sales should climb in the low double digits, with Neffy contributing more and more during the second-half year. Gross margin is now anticipated to match last year's level, which mirrors the robust tablet momentum across Europe. We continue to anticipate comparatively stronger growth in partner-related revenue at reduced margins over the rest of the year, chiefly from shipments into Japan and China plus Neffy sales, which likewise carry lower margins. Capacity costs are forecast to go up, yet the ratio of capacity costs to revenue should stay broadly flat, since ALK will reinvest the advantages of greater scale into key strategic growth opportunities. In summary, we expect to carry on our path of double-digit organic revenue growth, with an EBIT margin a little above our long-term earnings ambitions. We are, once more, highly pleased with the Q1 results and the present business momentum. With that, I return the floor to you, Per, and to slide 10.

Per Plotnikof executive
#15

Thanks, Claus, and thanks, Peter. That brings our presentation to a close, and now we'll begin the Q&A session. Operator, please go ahead.

Operator operator
#16

Thanks. We're moving into the Q&A portion now. To pose a question, just hit star followed by one on your touchtone device. Should you be on a speakerphone, lift the handset first before you press those keys. If your question gets answered at any point and you'd prefer to pull it, press star and then two. Right now we'll take a brief pause to put our roster together. Thomas Bowers from SEB has the first question. Go ahead, please.

Thomas Bowers analyst
#17

Yes, thanks a lot. I have three questions from my table here. First, regarding peanut, given the low incidence of adverse events that we saw in that phase 2 trial, do you think the high dose you used there was optimal? Is there room to go higher with dosing in phase 3 to improve efficacy, or do you feel that at the current level you are already near what could be called an efficacy ceiling? Second, just on the remaining risks concerning pricing reforms or interim discounts in Germany. As I understand it, the proposal right now is a 3.5% discount beginning January 2027, but you are still incorporating some risk in '26, or perhaps that is only the macro uncertainties. Is there any uncertainty around timelines here, and also that 3.5%, should we view this as a one-year interim measure, or what is the sort of planning here? Last question, just on ALK-014. This is the first time you have sort of disclosed the target. Should we view this as a potential next-generation Xolair? Is there anything different about 014 when it comes to blocking IgE, and also how should we compare this to, for example, omalizumab from Roche with the 3-month dosing?

Thomas Bowers analyst
#18

Is there anything that could set ALK-014 apart, considering you're a few years behind on that? Thank you.

Peter Halling executive
#19

Thank you, Thomas. I’ll begin with peanut, then have Claus address the risks and Germany, and finally I’ll comment on ALK-014. Obviously, we’ve been reviewing the phase 2 data and dosing. We think it appears to be the right range. Might a higher dose offer additional benefit? That comes down to examining dosing as well as safety, and we believe the current dosing puts us in a quite good position. At this stage—and I want to emphasize at this stage—we do not expect any dosing change given the positive results. More importantly, obviously, we obtained strong results in just 6 months, and we may gain from a longer timeline in the phase 3 trial. I believe that covers that question. Now, on the risk, Claus?

Claus Steensen Sølje executive
#20

Should I just accept that? Thanks, Thomas, for asking. Let me begin by noting that we're only at the start of May, correct? Other pricing risks could affect us later in the year that we aren't really aware of at this moment or at that moment. Let me concentrate on the German issue you raised. It's true that just last week in the German parliament, a proposal was put forward to have no German rebate at all for '26, but instead to begin on 1st of January 2027 at 3.5% on top of the existing 7%, which makes 10.5%. That proposal also suggested this would apply only during the first half of 2027, and then for the second half of 2027, they weren't really sure what to do, whether it should instead be a percentage that might track something. We don't know what that something is — it could be, for instance, price increases or medical prices in the market. What we're saying at this point is that this remains highly uncertain. It hasn't been implemented yet, and we don't really know what's going to happen.

Claus Steensen Sølje executive
#21

We've been hearing that some voices in the German parliament still believe the pharma industry is getting off too easy, if I can put it that way, here for '26, and that something should be implemented over the second half of the year. We don't know whether that's coming, which is why we're flagging it as a risk and as a potential downside. You're right that at the moment, it's more of a suggestion coming from 1st of January, and then that's it. Whether or not it's a one-year impact, we actually don't know yet. It could be a two- or three-year. They aren't very specific about that. I'll leave you with that.

Peter Halling executive
#22

Thanks, Claus. Regarding ALK-014, you asked if this is a next-generation Xolair, something Xolair-like. I'd say it's an anti-IgE. Of course, we're examining what's currently on the market, and we're also reviewing the data we have available, including what's been done in animals. Keep in mind this is preclinical, and we find it encouraging. We also believe, obviously, it's encouraging enough that we're weighing whether it should advance into a phase 1. This would be a natural extension in terms of our food allergy portfolio. I promise you, Thomas, we'll be able to share more as we progress, but we felt it was important to flag because we know it's a question that keeps coming up. We do have an interesting molecule. It works a bit differently than what you see otherwise, but we think it's highly relevant going forward as well, not only for food allergy, potentially for more indications given that it's a broad anti-IgE. I think I'll leave it there, and then I'll promise you that we'll return later in the year when we have a bit more clarity regarding where we stand and when we'll move it forward. If we do move it forward, the ambition will be to start it up around year-end and into the new year, and that would obviously be a phase 1, focusing on the safety aspects of the molecule in humans.

Peter Halling executive
#23

Okay, good. All right, I hope that covered it.

Thomas Bowers analyst
#24

That's great. Thank you.

Operator operator
#25

Our following question is from Benjamin Jackson at Jefferies. Your line is open.

Benjamin Jackson analyst
#26

Excellent. Thanks for the question. I have two areas to cover. First, if I may pick up where we left off on peanut and what you said regarding dosing, and you noted that this response was observed at 6 months, perhaps you could say what else might be done as we head into the phase 3 that could further boost the results you are seeing, for instance a longer maintenance period or something different during uptitration. Following on from that, looking at the data in hand right now, are you able to see response rates getting better over time, and would that therefore justify dosing out across a 12-month period, which appears to be more standard when you look at competitors in this food allergy space? Second, I want to touch briefly on M&A and potential BD. You are generating a lot of cash now with low leverage — is this becoming a larger part of your agenda or of portfolio decisions going forward? And following on from that, what should investors expect regarding the sizing and phenotype of any potential deals that happen? That would be great.

Benjamin Jackson analyst
#27

I appreciate that.

Peter Halling executive
#28

Thanks, Ben. This is Peter. Looks like I wound up covering both of them. <<laughter>>

Claus Steensen Sølje executive
#29

Appreciate it, Ben.

Peter Halling executive
#30

No, I think regarding the peanut, clearly a phase 3 has greater breadth and depth, given the prescriber bases and the population, or the cohorts, that we're enrolling. That by itself gives us chances to optimize even more. We clearly picked up a number of lessons about ways to make sure this runs still better, and hopefully that will also help improve the results, but that remains to be seen. Turning to the maintenance, we'll be looking at something probably closer to what you've seen from others running these trials, and we're doing that because we believe we'll see even better results than in the first part. As for the dosing up schemes, etc., that's clearly also a dialogue with the FDA regarding what their expectations are and what ours are. I'll hold off on answering that, but we clearly think about this from a prescriber standpoint as well as from a patient standpoint, so it becomes more efficacious and also easier for all parties involved when it comes to running and conducting the trial, but clearly also afterward, where we hope to launch the product. I think we'll clearly do what we can to optimize going forward.

Peter Halling executive
#31

Hopefully, the dialogue with the FDA will begin shortly, and then, as soon as possible, we'll discuss more broadly how the study design is being set up and how we're conducting it. Regarding M&A and BD&L, I think the brief answer is that we'll make an announcement <<laughter>> when and if we do more. That said, yes, we're aware that we're generating cash. We've said it consistently — this forms part of our strategy. We're looking on a continuous basis, but it comes down to both price and relevance for us as a company. I think the good news is that we still have plenty of things to do within our current business, areas in which to invest. I'll remind you of what we did at the Capital Markets Day. Organic growth remains a top priority for the company, and then inorganic growth in relevant areas and where we can help expand our portfolio — that can either be in-licensing, or it could also be M&A. If something is out there that can help us both from a portfolio standpoint, but also from a geographical standpoint, that could be relevant, and we will continue to monitor it. I'll promise you, as soon as we have something, we'll share it soon and if, just to be clear.

Peter Halling executive
#32

That's as far as I'm able to go on that, but I hope it at least provided you with some useful insight.

Benjamin Jackson analyst
#33

That's helpful. Thank you very much.

Operator operator
#34

Jesper Ilsøe from DNB has the next question. Go ahead, please.

Jesper Ingildsen analyst
#35

Yes, thank you. Jesper Ilsøe here from DNB Carnegie. I've got a few questions about the food allergy side as well, and then perhaps one on Neffy. First, on ALK-014, you've moved that into the clinic. I'm wondering whether you could say a bit more about the costs involved in potentially running clinical development for a biologic like an anti-IgE. How far do you think you can take this before you need to bring in a partner? I ask particularly given what we've been seeing from some of the large pharma companies evaluating assets in this area — take Novartis' score as an example from just a few weeks back. Then on tree nut, I don't see any mention of you advancing that right now. My understanding was that you intended to move that forward following positive phase 2 data in peanut. And finally, a question on Neffy: could we get an update on the market share achieved for it so far? I believe it stood at 18% at the end of '25 — is there any further progress? I appreciate Germany isn't yet the biggest market where you hold the licensing agreement, but I'm just trying to understand why it still isn't showing up more materially in the numbers.

Peter Halling executive
#36

Sure. Thanks, Jesper. Peter here again. Regarding ALK-014, just keep in mind that this is preclinical. We have to advance it. When we consider partnerships and similar matters, the most important thing, above all, is making sure we possess relevant data that we can examine closely—and clearly, potentially other parties could as well. That would seem natural alongside a phase 1. ALK has no plans to turn into a biologic company on a standalone basis. Having said that, when we hold interesting assets in the pipeline and generate a great deal of new knowledge, we clearly also consider it important to examine that and move it forward. When we consider trial designs and so on, it isn't very different from the way you would conduct AIT clinical studies—we are reasonably at ease carrying that out. The data will show us whether we think partners are needed or whether we can handle this ourselves. As for tree nut, tree nut remains relevant to the company, but clearly we are examining this from a portfolio perspective and also with ALK-014 and clearly with the peanut trial heading into a phase 3. We still need to receive some feedback from the FDA regarding what their expectations are for peanut, and we can apply that to guide us on how we ought to be approaching something like tree nut.

Peter Halling executive
#37

Just give us a little patience here. We're not doing that deliberately. The reason is simply that we have to complete the FDA interactions and sort of finalize the phase 3 design. That will also guide how we should think about tree nut potentially. Then on your Neffy question, basically when we look at Germany, the way we see it, there will be month-to-month fluctuations. We believe we've reached an initial plateau. We haven't done much to advance market share, but what we do like, and what the numbers show us, is that we're getting a growing number of patients on the product overall. Combined with Jext, we actually think our portfolio strategy is working quite well. As we mentioned earlier, both Claus and I discussed it, Neffy is expected to clear all the regulatory hurdles, the 1 mg approvals, but also individually in the local markets. Therefore, we also believe it becomes more meaningful to discuss uptake when we get into the later part of '26, most likely into '27, depending on the pace. Overall, to wrap up, I think we're in a pretty good place initially, but we're still talking low volumes overall, and that's also why we're a little cautious.

Peter Halling executive
#38

Our market share is still holding up well, and patient uptake looks fairly solid. Overall, things are positive.

Jesper Ingildsen analyst
#39

That's good.

Operator operator
#40

Sushila Hernandez from Van Lanschot Kempen has our next question. You have the floor.

Sushila Hernandez analyst
#41

Yes, thanks for taking my questions. Also, regarding the peanut program, does your base case look at the tablets in 4 to 65-year-olds, or could you possibly go lower as well? Could you give us more color on the discontinuation rates in the phase 2 study? Is there any difference across the age groups? Thank you.

Peter Halling executive
#42

Peter here. To answer your question, we're considering pushing the timeline shorter — essentially down to 1 year. Again, that obviously hinges on how things play out with FDA, but ideally that's what we'd do. It would mean broadening the program. Then there's the second part — Sushila, could you restate the second part of the question?

Sushila Hernandez analyst
#43

Right, on the phase 2 study’s discontinuation rates — is there any difference across the age groups? Could you give us a bit more color there?

Peter Halling executive
#44

Do Per? Honestly, I’m not sure how much —

Per Plotnikof executive
#45

At this point, we don’t have any additional details on that. It’ll be presented at a medical event, but keep in mind that discontinuation levels overall were very low. We’re talking about only a few patients on active treatments and a few on placebo as well. It was quite low. Discussing discontinuation levels across different age groups in a meaningful way is very difficult. The study is just too small to do that on a meaningful basis.

Sushila Hernandez analyst
#46

Got it. Thanks.

Operator operator
#47

Once more, should you have a question, press star followed by one. Our next question is from Peter Hugreffe Anker at Nordea. Go ahead, please.

Peter August Anker analyst
#48

Hello. This is Peter Hugreffe from Nordea, and I appreciate the chance to ask a few things. First, Claus, on the subject of margins: your longer-term guidance sits near 25%, yet we are now beginning to observe 26% and perhaps it is even trending higher. For 2020 through 2026 and past that, what framing should we use for how margins will develop? Is this merely a temporary blip, after which you return to the prior level, or what is the right way to view it? That is my first point. Second, the M&A conversation caught my interest. Could you give a bit more context on whether you are considering more transformational transactions, simply smaller bolt-ons, or something in between — any clarity would help. With that, I will hold off on further peanut questions for the moment. <<laughter>>

Peter Halling executive
#49

Thanks, Peter. Claus, over to you?

Claus Steensen Sølje executive
#50

Thanks, Peter. Good to hear from you. You're right that we've now increased to 26%, and of course we aren't guiding on next year's EBIT margin at this point, but I think what's interesting to take into consideration is that if you look into next year, that's when we're especially starting the peanut — which is also now kind of a peanut <<laughter>> matter — peanut phase 3 trial. So in '27 and '28, we're going to invest significantly in the peanut trials, and you'll see an increase there. Depending, of course, also — we talked about ALK-014, where that will go with the preclinical and so on — then you could also see increased investments into that. Overall, R&D investments will increase. On top of that, there's no doubt we'll continue our commercial investments, both with the children launches continuing to invest into that, but especially next year, also the Neffy launches across the world. That will be our second parameter as well. There's no doubt that next year, we'll aim for the 25% EBIT margin, as we have in our long-term financial targets, and that's of course a deliberate decision we're making to make sure that we invest for both top line and bottom line growth in the years to come.

Claus Steensen Sølje executive
#51

Hopefully, that gives you a sense of it.

Peter Halling executive
#52

Peter, while I'd enjoy diving deeper into the specifics of M&A and BD&L, it's hard to offer much more detail. Still, I think the key point to convey, and the way you ought to frame it, is that we have a company that continues to hold quite a few avenues for growth. Our consistent message has been that, looking across our segments, we see value in putting money into assets that support a portfolio strategy, allowing us to secure a strong global position, including in North America, the US, and Europe, but potentially in Asia too. Ideally, we'll keep expanding. The Neffy deal was a license arrangement that handed us a global asset—though it excluded the US and a handful of other countries—yet it made a meaningful contribution to our portfolio. That's our line of thinking. Naturally, we also consider this in relation to the food allergy space, and should something relevant emerge in respiratory, we'd be examining that as well. Clearly, we are reviewing possibilities. You're likewise seeing the price points in the market, and as for assets, it has to be significant for ALK too. I can't get any more specific than that,

Peter August Anker analyst
#53

But.

Peter Halling executive
#54

Clearly, that topic is on the agenda.

Peter August Anker analyst
#55

So could I put that question to you in reverse instead?

Peter Halling executive
#56

Give it a shot.

Peter August Anker analyst
#57

<<laughter>> Exactly. I know. Just regarding the cash that's accumulating, because you could argue that at some point, if everything goes according to plan, then you'll be sitting on a substantial pile of cash. How should we think about that? At what point do you start a huge buyback, or is it when you raise the dividend, or how should we think about that in terms of the cash you'll be piling up in the coming years if you live up to your expectations?

Peter Halling executive
#58

For me, the simpler topic is how we deploy the cash, while Claus prefers discussing how we hold onto it. Claus, would you like to say something? <<laughter>>

Claus Steensen Sølje executive
#59

Thank you. Thank you, Peter. I believe it's clear we've consistently stated that disciplined capital allocation is something we favor. Essentially, that means when you examine our capital structure and our approach, as Peter mentioned earlier, our preference is to put money into organic growth, and without question we'll direct as much of that cash as possible toward commercial opportunities, R&D opportunities, and so forth. Beyond that, we're also putting money into various areas, such as expanding our manufacturing capacity — where at present, for instance, we're able to make as many as those 500 million tablets, and we want to raise that to 800 million, up to a billion tablets as well. That's another area we'll be investing in over the coming years. And then, to be sure, we also stated at the Capital Markets Day that we're not a bank. Once we've invested enough in top-line organic growth, in the various facilities, and in the BD and M&A that Peter refers to — something hard to quantify at this moment — then should anything remain, our preference would be to give it back to the shareholders.

Claus Steensen Sølje executive
#60

So for the first time this year, that's what we did — we established a dividend at 30% of net profit. Naturally, there are alternative approaches, and as you pointed out yourself, it could be raising the dividends or exploring share buybacks. That might present another opportunity as well, though it's too early to discuss that at this point. We won't let cash just accumulate, and we won't turn into a bank. Once we've made investments in the future, which we see as the correct course, and if we reach the conclusion that there are no BD/M&A activities, we'll then examine boosting shareholder return. That's the plan.

Peter August Anker analyst
#61

Thanks a lot — I really appreciate it.

Peter Halling executive
#62

Appreciate that, Peter.

Peter August Anker analyst
#63

I really appreciate it.

Operator operator
#64

That brings our Q&A portion to an end. I'll now hand the conference back to management in case they have any closing remarks to share.

Per Plotnikof executive
#65

Thanks so much. Thanks, everyone, for those great questions. Before we wrap up the call, I’d like to point out a few events coming up that are shown on slide 11. We really hope you’ll join us at one of them. Either way, please feel free to reach out if you have any further questions or comments. That brings today’s session to a close. Goodbye, and have a wonderful day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete ALK-Abelló A/S transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to ALK-Abelló A/S earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.